CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma

CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma

Despite the improvement in survival outcomes, multiple myeloma (MM) remains an incurable disease. Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) represents a new strategy for the treatment of relapsed/refractory MM (R/R). In this paper, we describe several...

Full description

Bibliographic Details
Main Authors: Massimo Martino, Filippo Antonio Canale, Caterina Alati, Iolanda Donatella Vincelli, Tiziana Moscato, Gaetana Porto, Barbara Loteta, Virginia Naso, Massimiliano Mazza, Fabio Nicolini, Andrea Ghelli Luserna di Rorà, Giorgia Simonetti, Sonia Ronconi, Michela Ceccolini, Gerardo Musuraca, Giovanni Martinelli, Claudio Cerchione
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
multiple myeloma
BCMA
CAR T
relapsed multiple myeloma
refractory myeloma
cytokine release syndrome
Online Access:https://www.mdpi.com/2072-6694/13/11/2639

Internet

https://www.mdpi.com/2072-6694/13/11/2639

Similar Items